Il farmacista ospedaliero ha sempre ricoperto un ruolo rilevante nelle sperimentazioni cliniche. Tuttavia, ad oggi, le good clinical practice sul tema non vengono ancora applicate in modo uniforme: ne parliamo con Angelo Claudio Paolozzo.
Standard first-line therapy of chronic myeloid leukemia is treatment with imatinib. In the randomized German Chronic Myeloid Leukemia-Study IV, more potent BCR-ABL inhibition with 800mg (high-dose) imatinib accelerated achievement of a deep molecular remission. However, whether and when a de-escalation of the dose intensity under high-dose imatinib can be safely performed without increasing the risk of losing deep molecular response
Over the past decades, survival of patients with acute lymphoblastic leukemia (ALL) has dramatically improved, but the subgroup of patients with relapsed/refractory ALL still continues to have dismal prognosis.